Financials in USD. Standardized financial statements.
A compact view of how Biofrontera AG turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Revenue? | $34.07M | $28.67M | $24.10M | $18.85M | $26.18M |
| Revenue Growth? | +18.8% | +19.0% | +27.9% | -28.0% | 0.0% |
| Cost of Revenue? | $17.44M | $15.19M | $12.74M | $9.07M | $12.41M |
| Gross Profit? | $16.63M | $13.49M | $11.36M | $9.78M | $13.77M |
| Gross Margin? | +48.8% | +47.0% | +47.1% | +51.9% | +52.6% |
| Operating Expenses? | $39.96M | $35.87M | $37.21M | $18.12M | $28.70M |
| Operating Income? | -$22.68M | -$22.38M | -$25.85M | -$8.33M | -$14.92M |
| EBITDA? | -$18.45M | $934,000 | -$36.76M | -$7.49M | -$8.15M |
| Income Before Tax | -$20.12M | -$608,000 | -$37.66M | -$10.92M | -$10.95M |
| Income Tax Expense | $14,000 | $32,000 | $56,000 | $64,000 | $33,000 |
| Net Income? | -$20.13M | -$640,000 | -$37.71M | -$10.99M | -$10.98M |
| EPS? | $-13.02 | $-0.61 | $-44.10 | $-18.94 | $-18.09 |
| Diluted EPS? | $-13.02 | $-0.61 | $-44.10 | $-18.94 | $-18.09 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality